Global Hospital-acquired Pneumonia (HAP) Drugs Market 2017-2021
About Hospital Acquired Pneumonia (HAP) Drugs
HAP is a type of pneumonia that is caused after 48 hours of hospitalization. HAP is one of the major challenges faced by the public healthcare system today. The disease is the second most common type of hospital-acquired infections. Pneumonia is an inflammatory condition of lungs and mainly affects the microscopic air sacs called alveoli. This is primarily caused by infection by bacteria or viruses and sometimes with other microorganisms. It can be mainly distinguished on how the infection was acquired.
Technavio’s analysts forecast the global hospital acquired pneumonia drugs market to grow at a CAGR of 2.22% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global hospital acquired pneumonia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Hospital Acquired Pneumonia Drugs Market 2017-2021
Technavio recognizes the following companies as the key players in the global hospital acquired pneumonia drugs market: GlaxoSmithKline, Merck, Novartis, and Pfizer.
Other Prominent Vendors in the market are: Arsanis, AstraZeneca, Combioxin, Mylan, Shinogi, Sun Pharmaceutical Industries, Teva Pharmaceutical, The Medicines Company, and Theravance Biopharma.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is combination therapy for the treatment of HAP. Monotherapy is the common treatment given for nosocomial pneumonia. However, combination therapy has sometimes been found to be more appropriate and desirable treatment.”
According to the report, one driver in the market is unmet demand due to lack of available treatment for MDR microorganisms. Lack of proper treatment options available for the treatment of HAP because of MDR microorganisms is a major challenge for the healthcare providers. MDR microorganisms are those microorganisms that have developed antimicrobial drugs resistance. The resistance among various microorganisms to various antimicrobial drugs has emerged as a serious threat to public health across the globe.
Further, the report states that one challenge in the market is growing cases of MDR microorganisms. MDR microorganisms are the species of microorganisms that show resistance to multiple antimicrobial drugs. It may consist of bacteria, viruses, fungi, and many other parasites. MDR bacteria are the most threatening group of these microorganisms and have a huge impact on the public health. It is considered that approximately one-tenth of hospitalizations get complicated with healthcare-associated infections.
GlaxoSmithKline, Merck, Novartis, Pfizer, Arsanis, AstraZeneca, Combioxin, Mylan, Shinogi, Sun Pharmaceutical Industries, Teva Pharmaceutical, The Medicines Company, and Theravance Biopharma.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook